Janux lets the genie out of the bottle
A more comprehensive dataset on JANX007 sends the group’s stock down.
Amgen gets a full approval for Imdelltra
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
Amgen goes pivotal with subcutaneous Blincyto
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
Amgen's $1.9bn looks buried
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
Triple meeting 2025 – Zai discloses pivotal DLL3 plans
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
Tango waltzes towards phase 3
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
Triple meeting 2025 – Revolution hints at post-KRAS promise
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
ESMO 2025 – bemarituzumab fails to convince
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
Zelgen’s DLL3 trispecific goes pivotal
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
Merck shoots for KRAS all comers
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
